-
Cost Control Helps Amylin Cut Loss - Analyst Blog
Thursday, January 27, 2011 - 11:15am | 1270Amylin Pharmaceuticals (AMLN) reported a net loss of 8 cents per share in the fourth quarter of 2010, well below the Zacks Consensus Estimate and the year-ago loss of 32 cents. Full year 2010 loss came in at 94 cents, significantly below the Zacks Consensus Estimate of a loss of $1.26 and the...
-
Covance in Tune with Zacks Est. - Analyst Blog
Thursday, January 27, 2011 - 11:01am | 628Covance (CVD) reported an EPS of 45 cents for the fourth quarter of fiscal 2010 compared with 64 cents of the year-ago quarter. However, considering some adjustments, the EPS came in at 56 cents, beating the Zacks Consensus Estimate of 53 cents. For fiscal 2010, the adjusted EPS was $2.15,...
-
Covance in Tune with Zacks Est. - Analyst Blog
Thursday, January 27, 2011 - 10:30am | 628Covance (CVD) reported an EPS of 45 cents for the fourth quarter of fiscal 2010 compared with 64 cents of the year-ago quarter. However, considering some adjustments, the EPS came in at 56 cents, beating the Zacks Consensus Estimate of 53 cents. For fiscal 2010, the adjusted EPS was $2.15,...
-
Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56
Wednesday, January 26, 2011 - 5:16pm | 137Covance Inc. (NYSE: CVD) today reported GAAP earnings for its fourth quarter ended December 31, 2010 of $0.45 per diluted share. Included in fourth quarter results is $0.22 per diluted share in costs from the previously-announced fourth quarter restructuring actions, partially offset by a gain of...
-
Covance Reports Q4 EPS of $.56 vs. $.53
Wednesday, January 26, 2011 - 5:12pm | 137Covance Inc. (NYSE: CVD) today reported GAAP earnings for its fourth quarter ended December 31, 2010 of $0.45 per diluted share. Included in fourth quarter results is $0.22 per diluted share in costs from the previously-announced fourth quarter restructuring actions, partially offset by a gain of...
-
Top 4 Mid-Cap Stocks In The Medical Laboratories & Research Industry With The Highest EPS Estimates (LH, DGX, CVD, ALR)
Wednesday, January 26, 2011 - 4:36am | 151Below are the top mid-cap medical laboratories & research stocks on the NYSE and the NASDAQ in terms of earnings estimate for the next quarter. The earnings estimate for Laboratory Corp of America Holdings (NYSE: LH) for the next quarter ending March, 2011 is $1.37 per share. LH's trailing-...
-
Waters Outperforms - Analyst Blog
Tuesday, January 25, 2011 - 5:01pm | 676Waters Corporation (WAT) released its fourth quarter earnings before the market opened today, reporting earnings from continuing operation of $1.38, above the Zacks Consensus Estimate of $1.31. Earnings in the quarter increased by 23% from $1.12 in the third quarter of 2009. The company's...
-
Stocks on the Move (PPDI) Breaking out
Tuesday, January 25, 2011 - 4:52pm | 14Stocks on the Move (PPDI) Breaking out
-
Stocks on the Move (PPDI) Breaking out
Tuesday, January 25, 2011 - 4:51pm | 14Stocks on the Move (PPDI) Breaking out
-
Waters Outperforms - Analyst Blog
Tuesday, January 25, 2011 - 4:42pm | 676Waters Corporation (WAT) released its fourth quarter earnings before the market opened today, reporting earnings from continuing operation of $1.38, above the Zacks Consensus Estimate of $1.31. Earnings in the quarter increased by 23% from $1.12 in the third quarter of 2009. The company's...
-
Jefferies Prime Time AM Tickers
Tuesday, January 25, 2011 - 11:53am | 186Jefferies is out with a research report on various changes to its roster of companies. This morning, Jefferies initiated coverage on Elan (NYSE: ELN), rating the company a Buy with a $12 price target. In terms of price target changes, Jefferies changed Autodesk (NASDAQ: ADSK) to $41 from $37, Bank...
-
Boost for VRX-GSK Epilepsy Drug - Analyst Blog
Tuesday, January 25, 2011 - 11:01am | 579Valeant Pharmaceuticals International (VRX) and GlaxoSmithKline plc (GSK) recently said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of epilepsy drug, retigabine. The companies had submitted the Marketing Authorization...
-
Boost for VRX-GSK Epilepsy Drug - Analyst Blog
Tuesday, January 25, 2011 - 10:45am | 579Valeant Pharmaceuticals International (VRX) and GlaxoSmithKline plc (GSK) recently said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of epilepsy drug, retigabine. The companies had submitted the Marketing Authorization...
-
Waters Conference Call Today at 8:30am, Deutsche Bank To Report After
Tuesday, January 25, 2011 - 9:50am | 140Deutsche Bank has published a research report on Waters Corporation (NYSE: WAT) after the company reported 4Q EPS well above consensus estimates. In the report, Deutsche Bank writes "WAT kicked off the 4Q reporting season for the LST group with very strong results, highlighting the continued...
-
Caliper Life Sciences - Aggressive Growth
Tuesday, January 25, 2011 - 3:01am | 430Caliper Life Sciences (CALP) recently announced preliminary financial results that breathed some life into the stock. Estimates are moving higher as a result. CALP currently has a Zacks #1 Rank (Strong Buy) and continues to expand into new markets. Company Description Caliper Life Sciences...